Skip to search formSkip to main contentSkip to account menu

CBP 501

Known as: CBP-501, CBP501 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cdc25C phosphatase (211-221)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts.
3059Background: CBP501 is a 12-amino acid G2 checkpoint abrogator and calmodulin-modulating peptide that increases platinum… 
2019
2019
Abstract CT228: Phase Ib clinical study of CBP501, cisplatin and nivolumab administered every 3 weeks in patients with advanced refractory tumors. Dose escalation cohort
Background: CBP501 is a 12 amino acid calmodulin-modulating peptide that increases platinum influx into tumor cells and induces… 
2014
2014
Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patients with… 
2012
2012
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).
7029 Background: CBP501, a synthetic duodecapeptide, enhances the cytotoxicity of cisplatin in cell lines and xenografts… 
2011
2011
Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site.
2011
2011
Preclinical Development CBP 501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin
CBP501 is an anticancer drug currently in randomized phase II clinical trials for patientswith non–small cell lung cancer and… 
2011
2011
Abstract 2635: CBP501-calmodulin binding contributes to sensitizing tumor cells to CDDP and BLM
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL CBP501 is an anti-cancer drug candidate currently under… 
2009
2009
Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies
Background: CBP501 is a synthetic peptide that appears to increase intracellular CDDP and enhance DNA damage caused by bleomycin… 
2008
2008
Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts)
2528 Background: Most cancer cells are dependent on the G2 checkpoint to survive with DNA damage. The stable peptide CBP501 shows… 
2008
2008
Gateways to clinical trials. July-August 2008.
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)